The North America sarcopenia treatment market is expected to reach USD 1,814,892.90 thousand by 2030 from USD 1,235,920.05 thousand in 2022, growing at a CAGR of 5.0% during the forecast period of 2023 to 2030. Market Segmentation North America Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, And Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) Country ( U.S., Canada, and Mexico) – Industry Trends and Forecast to 2030 Overview of North America Sarcopenia Treatment Market Dynamics Drivers • Rising prevalence of sarcopenia • Growing awareness of sarcopenia and its detrimental effects on health Restraint • Lack of standardized diagnosis Opportunity • Strategic initiatives by market players Market Players Some of the major market players operating in the North America sarcopenia treatment market are: • Abbott. • Nestlé Health Science ( A subsidary of Nestlé S.A.) • Novartis AG • Sanofi • Haleon Group of Companies. • BASF SE • Bio Thrive Sciences • DSM • Fermenta Biotech Limited • AstaReal Co., Ltd. • Metagenics • Wellona Pharma • The Vitamin Company India • Healing Pharma India Pvt. Ltd. • OPKO Health, Inc. • MyMD Pharmaceuticals • Regeneron Pharmaceuticals Inc. • Biophytis • ARMGO Pharma, Inc. • Dystrogen Therapeutics Corp.

1 INTRODUCTION 14 1.1 OBJECTIVES OF THE STUDY 14 1.2 MARKET DEFINITION 14 1.3 OVERVIEW OF THE NORTH AMERICA SARCOPENIA TREATMENT MARKET 14 1.4 CURRENCY AND PRICING 16 1.5 LIMITATIONS 16 1.6 MARKETS COVERED 16 2 MARKET SEGMENTATION 18 2.1 MARKETS COVERED 18 2.2 GEOGRAPHICAL SCOPE 19 2.3 YEARS CONSIDERED FOR THE STUDY 19 2.4 DBMR TRIPOD DATA VALIDATION MODEL 20 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 23 2.6 MULTIVARIATE MODELLING 24 2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 24 2.8 MARKET END USER COVERAGE GRID 25 2.9 DBMR MARKET POSITION GRID 26 2.10 SECONDARY SOURCES 28 2.11 ASSUMPTIONS 28 3 EXECUTIVE SUMMARY 29 4 PREMIUM INSIGHTS 32 4.1 PESTEL ANALYSIS 34 4.2 PORTER’S FIVE FORCES 35 5 NORTH AMERICA SARCOPENIA TREATMENT MARKET: REGULATIONS 36 5.1 REGULATIONS IN THE U.S 36 5.2 REGULATIONS IN CANADA 36 5.3 REGULATIONS IN MEXICO 37 6 MARKET OVERVIEW 38 6.1 DRIVERS 40 6.1.1 RISING PREVALENCE OF SARCOPENIA 40 6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 40 6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 41 6.2 RESTRAINTS 42 6.2.1 LACK OF STANDARDIZED DIAGNOSIS 42 6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 42 6.3 OPPORTUNITIES 43 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 43 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 43 6.4 CHALLENGES 44 6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 44 6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 45 7 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 46 7.1 OVERVIEW 47 7.2 VITAMIN/DIETARY SUPPLEMENTS 50 7.2.1 VITAMIN SUPPLEMENTS 50 7.2.2 PROTEIN SUPPLEMENTS 50 7.2.3 FATTY ACID SUPPLEMENTS 51 7.2.4 CREATINE 51 7.2.5 WHEY PROTEINS 51 7.2.6 L-CARNITINE 51 7.2.7 SOY 51 7.2.8 BETA-ALANINE 51 7.2.9 OSTARINE 51 7.2.10 COLLAGEN PEPTIDES 51 7.2.11 LIGANDROL 51 7.2.12 BRANCH-CHAIN AMINO ACIDS 52 7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 52 7.2.14 MEDIUM CHAIN TRIGLYCERIDES 52 7.2.15 OTHERS 52 7.3 MEDICATIONS 52 7.3.1 OFF LABEL DRUGS 52 7.3.2 EMERGING DRUGS 53 7.3.2.1 ACE INHIBITORS 53 7.3.2.2 APPETITE STIMULANTS 53 7.3.2.3 ORAL ANTIDIABETIC DRUGS 53 7.3.2.4 OTHERS 53 7.4 OTHERS 53 8 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TYPE 54 8.1 OVERVIEW 55 8.2 PRIMARY SARCOPENIA 58 8.2.1 VITAMIN/DIETARY SUPPLEMENTS 58 8.2.2 MEDICATIONS 58 8.2.3 OTHERS 58 8.3 SECONDARY SARCOPENIA 59 8.3.1 VITAMIN/DIETARY SUPPLEMENTS 59 8.3.2 MEDICATIONS 59 8.3.3 OTHERS 59 9 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY STAGES 60 9.1 OVERVIEW 61 9.2 PRE-SARCOPENIA 64 9.3 SARCOPENIA 64 9.4 SEVERE SARCOPENIA 64 10 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 65 10.1 OVERVIEW 66 10.2 ORAL 69 10.3 INJECTABLES 69 10.4 OTHERS 69 11 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY GENDER 70 11.1 OVERVIEW 71 11.2 MALE 74 11.3 FEMALE 74 12 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY END USER 75 12.1 OVERVIEW 76 12.2 HOSPITALS 79 12.2.1 PUBLIC 79 12.2.2 PRIVATE 79 12.3 SPECIALTY CLINICS 79 12.4 HOME HEALTHCARE 79 12.5 OTHERS 79 13 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 80 13.1 OVERVIEW 81 13.2 DIRECT TENDER 84 13.3 RETAIL SALES 84 13.3.1 HOSPITAL PHARMACIES 84 13.3.2 ONLINE PHARMACIES 84 13.3.3 OTHERS 84 13.4 OTHERS 84 14 NORTH AMERICA SARCOPENIA TREATMENT MARKET BY COUNTRY 85 14.1 NORTH AMERICA 85 14.1.1 U.S 88 14.1.2 CANADA 93 14.1.3 MEXICO 98 15 NORTH AMERICA SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 103 15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 103 16 SWOT ANALYSIS 104 17 COMPANY PROFILE 105 17.1 ABBOTT 105 17.1.1 COMPANY SNAPSHOT 105 17.1.2 REVENUE ANALYSIS 105 17.1.3 PRODUCT PORTFOLIO 106 17.1.4 RECENT DEVELOPMENT 106 17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.) 107 17.2.1 COMPANY SNAPSHOT 107 17.2.2 REVENUE ANALYSIS 107 17.2.3 PRODUCT PORTFOLIO 108 17.2.4 RECENT DEVELOPMENT 108 17.3 NOVARTIS AG 109 17.3.1 COMPANY SNAPSHOT 109 17.3.2 REVENUE ANALYSIS 109 17.3.3 PRODUCT PORTFOLIO 110 17.3.4 PIPELINE PORTFOLIO 110 17.3.5 RECENT DEVELOPMENT 110 17.4 SANOFI 111 17.4.1 COMPANY SNAPSHOT 111 17.4.2 REVENUE ANALYSIS 111 17.5 PRODUCT PORTFOLIO 112 17.5.1 RECENT DEVELOPMENT 112 17.6 HALEON GROUP OF COMPANIES 113 17.6.1 COMPANY SNAPSHOT 113 17.6.2 REVENUE ANALYSIS 113 17.6.3 PRODUCT PORTFOLIO 114 17.6.4 RECENT DEVELOPMENT 114 17.7 ASTAREAL CO., LTD 115 17.7.1 COMPANY SNAPSHOT 115 17.7.2 PRODUCT PORTFOLIO 115 17.7.3 RECENT DEVELOPMENT 115 17.8 BASF SE 116 17.8.1 COMPANY SNAPSHOT 116 17.8.2 REVENUE ANALYSIS 116 17.8.3 PRODUCT PORTFOLIO 117 17.8.4 RECENT DEVELOPMENT 117 17.9 BIOTHRIVE SCIENCES 118 17.9.1 COMPANY SNAPSHOT 118 17.9.2 PRODUCT PORTFOLIO 118 17.9.3 RECENT DEVELOPMENT 118 17.10 DSM 119 17.10.1 COMPANY SNAPSHOT 119 17.10.2 REVENUE ANALYSIS 119 17.10.3 PRODUCT PORTFOLIO 120 17.10.4 RECENT DEVELOPMENT 120 17.11 FERMENTA BIOTECH LIMITED 121 17.11.1 COMPANY SNAPSHOT 121 17.11.2 REVENUE ANALYSIS 121 17.11.3 PRODUCT PORTFOLIO 122 17.11.4 RECENT DEVELOPMENT 122 17.12 HEALING PHARMA INDIA PVT.IND 123 17.12.1 COMPANY SNAPSHOT 123 17.12.2 PRODUCT PORTFOLIO 123 17.12.3 RECENT DEVELOPMENT 123 17.13 METAGENICS 124 17.13.1 COMPANY SNAPSHOT 124 17.13.2 PRODUCT PORTFOLIO 124 17.13.3 RECENT DEVELOPMENT 124 17.14 THE VITAMIN COMPANY INDIA 125 17.14.1 COMPANY SNAPSHOT 125 17.14.2 PRODUCT PORTFOLIO 125 17.14.3 RECENT DEVELOPMENT 125 17.15 WELLONA PHARMA 126 17.15.1 COMPANY SNAPSHOT 126 17.15.2 PRODUCT PORTFOLIO 126 17.15.3 RECENT DEVELOPMENT 126 17.16 ARMGO PHARMA, INC 127 17.16.1 COMPANY SNAPSHOT 127 17.16.2 PIPELINE PORTFOLIO 127 17.16.3 RECENT DEVELOPMENT 127 17.17 BIOPHYTIS 128 17.17.1 COMPANY SNAPSHOT 128 17.17.2 PIPELINE PORTFOLIO 128 17.17.3 RECENT DEVELOPMENT 128 17.18 DYSTROGEN THERAPEUTICS CORP 129 17.18.1 COMPANY SNAPSHOT 129 17.18.2 PIPELINE PORTFOLIO 129 17.18.3 RECENT DEVELOPMENT 129 17.19 MYMD PHARMACEUTICALS 130 17.19.1 COMPANY SNAPSHOT 130 17.19.2 PIPELINE PORTFOLIO 130 17.19.3 RECENT DEVELOPMENT 130 17.20 OPKO HEALTH, INC 131 17.20.1 COMPANY SNAPSHOT 131 17.20.2 REVENUE ANALYSIS 131 17.20.3 PIPELINE PORTFOLIO 132 17.20.4 RECENT DEVELOPMENT 132 17.21 REGENERON PHARMACEUTICALS INC 133 17.21.1 COMPANY SNAPSHOT 133 17.21.2 REVENUE ANALYSIS 133 17.21.3 PIPELINE PORTFOLIO 134 17.21.4 RECENT DEVELOPMENT 134 18 QUESTIONNAIRE 135 19 RELATED REPORTS 138